ACM Research, Inc.: Form 10-Q for the period ended Mar 31, 2025
Filed with the SEC on May 12, 2025 and accepted by EDGAR at May 12, 2025, 16:01 ET.
Management's discussion and analysis
As filed, 63,947 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
You should read the following discussion of our financial condition and results of operations together with our condensed consolidated financial statements and the related notes and other financial information included elsewhere in this report and our Annual Report on Form 10-K for the fiscal year ended December 31, 2024, or our Annual Report. The following discussion contains forward‑looking statements that reflect our plans, estimates, and beliefs. Our actual results could differ materially from those discussed in the forward‑looking statements. Factors that could cause or contribute to these differences include those discussed in Part I, Item 1A. “Risk Factors” in our Annual Report, as well as those discussed below and elsewhere in this report, particularly in the section titled “Item 1A – Risk Factors” in Part II below.
ACM Research, Inc., or ACM Research, is a Delaware corporation founded in California in 1998 to supply capital equipment developed for the global semiconductor industry. Since 2005, ACM Research has conducted its business operations principally through its subsidiary ACM Research (Shanghai), Inc., or ACM Shanghai, a limited liability corporation formed by ACM Research in the People’s Republic of China, or mainland China, in 2005. Unless the context requires otherwise, references in this report to “our company,” “our,” “us,” “we” and similar terms refer to ACM Research, Inc. and its subsidiaries, including ACM Shanghai, collectively.
Our principal corporate office is located in Fremont, California. We conduct a substantial majority of our product development, manufacturing, support and services in mainland China through ACM Shanghai. We perform, through a subsidiary of ACM Shanghai, additional product development and subsystem production in Korea, and we conduct, through ACM Research, sales and marketing activities focused on sales of ACM Shanghai products in North America, Europe and certain regions in Asia outside mainland China.
ACM Research is not a mainland China operating company, and we do not conduct our operations in mainland China through the use of a variable interest entity, or VIE, or any other structure designed for the purpose of avoiding mainland China legal restrictions on direct foreign investments in mainland China-based companies. ACM Research has a direct ownership interest in ACM Shanghai as the result of its holding 81.1% of the outstanding shares of ACM Shanghai. Stockholders of ACM Research may never directly own equity interests in ACM Shanghai. We do not believe that our corporate structure or any other matters relating to our business operations require that we obtain any permissions or approvals from the China Securities Regulatory Commission, the Cyberspace Administration of China, or any other mainland China central government authority in order to continue to list shares of Class A common stock of ACM Research on the Nasdaq Global Select Market. This determination was based on the facts aforementioned and mainland China Company Law, mainland China Securities Law, cybersecurity regulations and other relevant laws, regulations and regulatory requirements in mainland China currently in effect. However, if this determination proves to be incorrect, then it could have a material adverse effect on ACM Research. See “Item IA. Risk Factors—Risks Related to International Aspects of Our Business—If any mainland China central government authority were to determine that existing mainland China laws or regulations require that ACM Shanghai obtain the authority’s permission or approval to continue the listing of ACM Research’s Class A common stock in the United States or if those existing mainland China laws and regulations, or interpretations thereof, were to change to require such permission or approval, or if we inadvertently conclude that permissions or approvals are not required, ACM Shanghai may be unable to obtain the required permission or approval or may only be able to obtain such permission or approval on terms and conditions that impose material new restrictions and limitations on operation of ACM Shanghai, either of which could have a material adverse effect on our business, financial condition, results of operations, reputation and prospects and on the trading price of ACM Research Class A common stock, which could decline in value or become worthless” in our Annual Report.
In addition, in the ordinary course of business, ACM Shanghai is required to obtain certain operating permits and licenses necessary for it to operate in mainland China, including business licenses, certifications relating to quality management standards, import and export-related qualifications from customs, as well as environmental and construction permits, licenses and approvals relating to construction projects. We believe ACM Shanghai has all such required permits and licenses. However, from time to time mainland China government issues new regulations, which may require additional actions on the part of ACM Shanghai to comply. If ACM Shanghai does not, or is unable to, obtain any such additional permits or licenses, ACM Shanghai may be subjected to restrictions and penalties imposed by the relevant mainland China regulatory authorities, and it could have a material adverse effect on our business, financial condition, results of operations, reputation and prospects and on the trading price of ACM Research Class A common stock, which could decline in value or become worthless.
The following chart depicts our corporate organization as of March 31, 2025:
A detailed description of how cash is transferred through our organization is set forth under “Note 2 – Summary of Significant Accounting Policies – Cash and Cash Equivalents” to the Condensed Consolidated Financial Statements of this report.
The U.S. Holding Foreign Companies Accountable Act, or the HFCA Act, requires that the Public Company Accounting Oversight Board, or the PCAOB, determine whether it is unable to inspect or investigate completely registered public accounting firms located in a non-U.S. jurisdiction because of a position taken by one or more authorities in any non-U.S. jurisdiction. Under current regulations, if ACM Research were to be included on the SEC's "Conclusive list of issuers identified under the HFCA Act" for two consecutive years due to our independent auditor being located in a jurisdiction that does not allow for PCAOB inspections, the SEC would prohibit trading in our securities and this ultimately could cause our securities to be delisted in the U.S., and their value may significantly decline or become worthless. See “Item 1A. Risk Factors—Risks Related to International Aspects of Our Business—We could be adversely affected if we are unable to comply with legislation and regulations regarding improved access to audit and other information and audit inspections of accounting firms, including registered public accounting firms, such as our prior and current audit firms, operating in mainland China” in our 2024 Annual Report for more information.
Effective on December 2, 2024, the U.S. Department of Commerce’s Bureau of Industry and Security (“BIS”) promulgated a final rule naming a number of companies to the BIS Entity List (the "BIS Entity List"). Among the 140 companies added to the BIS Entity List were two subsidiaries of ACM Research, ACM Shanghai, located in the People’s Republic of China, and ACM Korea, a direct subsidiary of ACM Shanghai, which is located in the Republic of Korea, and other related entities. In general terms, the new BIS Entity List designations prohibit any party worldwide from furnishing hardware, software, or technologies that are subject to U.S. export controls jurisdiction directly or indirectly to ACM Shanghai or ACM Korea without obtaining authorization. See “Item 1A. Risk Factors—Regulatory Risks—Our operations in mainland China and Korea, including the import of components, technology, and activities of U.S. personnel therein, may be further impacted by the addition of ACM Shanghai, ACM Korea and related entities to the BIS Entity List” in our 2024 Annual Report for more information.
On November 15, 2024, the U.S. Department of the Treasury published a final rule implementing a framework for the regulation of outbound foreign investment from the United States. The new program, known as the Outbound Investment Security Program (“OISP”) was codified in the United States Code of Federal Regulations at 31 C.F.R. Part 850, effective as of January 2, 2025. The OISP marks a shift in U.S. economic policy, as historically the United States government declined to restrict outbound investment from the United States for national security reasons. Going forward, the investment activities of multinational companies, including ACM Research are subject to both CFIUS and OISP requirements, which together will limit cross-border investment opportunities, especially as they relate to China. See “Item 1A. Risk Factors—Regulatory Risks—The U.S. Government has implemented an outbound investment review mechanism, which may prevent us from taking advantage of investment opportunities outside the United States that could otherwise be advantageous to our stockholders” in our 2024 Annual Report for more information.
In addition to the matters discussed above, we are also subject to a number of legal and operational risks associated with our corporate structure, including as the result of a substantial portion of our operations being conducted in mainland China. Consequences of any of those risks could result in a material adverse change in our operations or cause the value of ACM Research Class A common stock to significantly decline in value or become worthless. Please carefully read the information included in “Item 1A. Risk Factors” in our 2024 Annual Report, in particular the risk factors addressing the following issues:
- If any mainland China central government authority were to determine that existing mainland China laws or regulations require that ACM Shanghai obtain the authority’s permission or approval to continue the listing of ACM Research’s Class A common stock in the United States or if those existing mainland China laws and regulations, or interpretations thereof, were to change to require such permission or approval, or if we inadvertently conclude that such permissions or approvals are not required, ACM Shanghai may be unable to obtain the required permission or approval or may only be able to obtain such permission or approval on terms and conditions that impose material new restrictions and limitations on operation of ACM Shanghai, either of which could have a material adverse effect on our business, financial condition, results of operations, reputation and prospects and on the trading price of ACM Research Class A common stock, which could decline in value or become worthless.
- Mainland China central government authorities may intervene in, or influence, ACM Shanghai’s mainland China-based operations at any time, and those authorities’ rules and regulations in mainland China can change quickly with little or no advance notice.
- The mainland China central government may determine to exert additional control over offerings conducted overseas or foreign investment in mainland China-based issuers, which could result in a material change in operations of ACM Shanghai and cause significant declines in the value of ACM Research Class A common stock, or make them worthless.
In addition to the matters discussed above, we are also subject to a number of legal and operational risks associated with our corporate structure, including as the result of a substantial portion of our operations being conducted in mainland China. Consequences of any of those risks could result in a material adverse change in our operations or cause the value of ACM Research Class A common stock to significantly decline in value or become worthless. Please carefully read the information included in “Item 1A. Risk Factors” in our Annual Report, in particular the risk factors addressing the following issues:
- If any mainland China central government authority were to determine that existing mainland China laws or regulations require that ACM Shanghai obtain the authority’s permission or approval to continue the listing of ACM Research’s Class A common stock in the United States or if those existing mainland China laws and regulations, or interpretations thereof, were to change to require such permission or approval, or if we inadvertently conclude that permissions or approvals are not required, ACM Shanghai may be unable to obtain the required permission or approval or may only be able to obtain such permission or approval on terms and conditions that impose material new restrictions and limitations on operation of ACM Shanghai, either of which could have a material adverse effect on our business, financial condition, results of operations, reputation and prospects and on the trading price of ACM Research Class A common stock, which could decline in value or become worthless.
- Mainland China central government authorities may intervene in, or influence, ACM Shanghai’s mainland China-based operations at any time, and those authorities’ rules and regulations in mainland China can change quickly with little or no advance notice.
- The mainland China central government may determine to exert additional control over offerings conducted overseas or foreign investment in mainland China-based issuers, which could result in a material change in operations of ACM Shanghai and cause significant declines in the value of ACM Research Class A common stock, or make them worthless.
Past statements and regulatory actions by mainland China central government authorities with respect to the use of VIEs and to data security and anti-monopoly concerns have not affected our ability to conduct our business operations in mainland China. For further information, see “Item 1A. Risk Factors —Risks Related to International Aspects of Our Business” in our Annual Report for more information.
Overview
We supply advanced, innovative capital equipment developed for the global semiconductor industry. Fabricators of advanced integrated circuits, or chips, can use our wet-cleaning and other front-end processing tools in numerous steps to improve product yield, even at increasingly advanced process nodes. We have designed these tools for use in fabricating foundry, logic and memory chips, including dynamic random-access memory, or DRAM, and 3D NAND-flash memory chips. We also develop, manufacture and sell a range of advanced packaging tools to wafer assembly and packaging customers.
Since 2009 we have delivered more than 1,180 tools to our customers, more than 980 of which were repeat orders or acceptances upon contractual performance obligations having been met and thereby generated revenue to us. The balance of the delivered tools is subject to the customer's acceptance of the tool upon the tool's satisfaction of applicable contractual requirements or subject to the customer's subsequent discretionary commitment to purchase the tool. To date, substantially all of our sales of equipment for semiconductor-manufacturing have been to customers located in Asia, and we anticipate that a substantial majority of our revenue from these products will continue to come from customers located in this region for the foreseeable future. We have begun to add to our efforts to further address customers in North America, Western Europe and Southeast Asia, by expanding our direct sales teams and increasing our global marketing activities.
Recent Developments
ACM Shanghai Proposed Private Offering
In January 2024, ACM Research announced ACM Shanghai's intended plan to offer up to 43.6 million of its ordinary shares, subject to market conditions, the approval of ACM Shanghai’s stockholders, completion of the review process by the Shanghai Stock Exchange, completion of the registration process by the China Securities Regulatory Commission, and other factors, in a private offering to qualified buyers, in compliance with the requirements of the China Securities Regulatory Commission, which would constitute up to 10% of ACM Shanghai’s share capital prior to the transaction (the “Private Offering”).
ACM Research estimates that if consummated in full, the proposed Private Offering would generate gross proceeds of up to RMB 4.5 billion ($642.2 million) to ACM Shanghai, whose management would have broad discretion over the use of such proceeds. It is unlikely that any of such proceeds would be distributed to ACM Research. ACM Research's equity interest in ACM Shanghai, if the proposed Private Offering is consummated in full, would decline from 81.1% to approximately 74.6%. As of March 31, 2025 and the date of this report, the proposed Private Offering has not been completed.
Mainland China Government Research and Development Funding
Since 2008, ACM Shanghai has received various government grants for the development and commercialization of certain technologies, and the development of the R&D and production center in the Lingang Special Area of Shanghai (note 12).
The governmental grants contain certain operating conditions, and we are required to complete a government due diligence process once the project is complete. The grants therefore are recorded as long-term liabilities upon receipt, although we are not required to return any funds ACM Shanghai receives.
Grant amounts are recognized in our statements of comprehensive income as follows:
- Government subsidies relating to current expenses are recorded as reductions of those expenses in the periods in which the current expenses are recorded. For the three months ended March 31, 2025 and 2024, related government subsidies recognized as reductions of relevant expenses in the consolidated statements of comprehensive income were $0.3 million and $0.4 million, respectively.
- Government subsidies related to depreciable assets are credited to income over the useful lives of the related assets for which the grant was received. Government subsidies related to VAT reduction are credited to income in the period received. For the three months ended March 31, 2025 and 2024, related government subsidies recognized as other income in the consolidated statements of comprehensive income were $0.3 million and $1.8 million, respectively.
Recent Accounting Pronouncements
A discussion of recent accounting pronouncements is included in our Annual Report and is updated in Note 2 to the condensed consolidated financial statements included in this report.
Net Income Attributable to Non-Controlling Interests
In 2019 ACM Shanghai sold a total number of shares representing 8.3% of its outstanding ACM Shanghai shares, after which ACM Research held the remaining 91.7% of ACM Shanghai’s outstanding shares. In 2021 ACM Shanghai sold a total number of shares representing an additional 10% of its outstanding ACM Shanghai shares in its STAR IPO, after which ACM Research held the remaining 82.5% of ACM Shanghai’s outstanding shares. ACM Research's ownership has since declined to 81.1% due to the exercise of stock options related to ACM Shanghai shares. As a result, we reflect the portion of our net income allocable to the minority holders of ACM Shanghai shares as net income attributable to non-controlling interests.
Critical Accounting Policies and Estimates
In preparing our condensed consolidated financial statements in conformity with GAAP, we make assumptions, judgments and estimates in applying our accounting policies that can have a significant impact on our revenue, operating income and net income, as well as on the value of certain assets and liabilities on our condensed consolidated balance sheets. We base our assumptions, judgments and estimates on historical experience and various other factors that we believe to be reasonable under the circumstances. At least quarterly, we evaluate our assumptions, judgments and estimates and make changes as deemed necessary. Actual results could differ materially from these estimates under different assumptions or conditions.
We believe that the assumptions, judgments and estimates involved in the accounting for the following accounting policies have the greatest potential impact on our condensed consolidated financial statements, and we therefore consider these to be our critical accounting estimates. For information on our significant accounting policies, see Note 2 in the notes to condensed consolidated financial statements in Part I, Item 1 of this report and in the Notes to Condensed Consolidated Financial Statements in Part II, Item 8 of our Annual Report, describe the significant accounting policies and methods used in the preparation of the Company’s condensed consolidated financial statements. There have been no material changes to the Company’s critical accounting estimates included in our Annual Report.
Results of Operations
The following table sets forth our results of operations for the periods presented, as percentages of revenue.
| Three Months Ended March 31, 2025 | 2024 | |
|---|---|---|
| Revenue | 100.0% | 100.0% |
| Cost of revenue | 52.1 | 48.0 |
| Gross margin | 47.9 | 52.0 |
| Operating expenses: | ||
| Sales and marketing | 9.5 | 9.3 |
| Research and development | 16.0 | 15.7 |
| General and administrative | 7.5 | 10.4 |
| Total operating expenses | 33.0 | 35.4 |
| Income from operations | 14.9 | 16.6 |
| Interest income, net | 1.0 | 0.6 |
| Realized gain from sale of short-term investments | 0.0 | 0.2 |
| Unrealized loss on short-term investments | -0.6 | -1.7 |
| Other (expense) income, net | -0.2 | 2.0 |
| Income (loss) from equity method investments | 0.6 | -0.3 |
| Income before income taxes | 15.7 | 17.4 |
| Income tax expense | -1.2 | -2.9 |
| Net income | 14.5 | 14.5 |
| Less: Net income attributable to non-controlling interests | 2.7 | 3.0 |
| Net income attributable to ACM Research, Inc. | 11.8% | 11.5% |
Comparison of Three Months Ended March 31, 2025 and 2024
Revenue
(in thousands)
| Three Months Ended March 31, 2025 | 2024 | % Change 2025 v 2024 | Absolute Change 2025 v 2024 | |
|---|---|---|---|---|
| Single wafer cleaning, Tahoe and semi-critical cleaning equipment | $129,569 | $109,470 | 18.4% | $20,099 |
| ECP (front-end and packaging), furnace and other technologies | 27,630 | 25,800 | 7.1% | 1,830 |
| Advanced packaging (excluding ECP), services & spares | 15,148 | 16,921 | (10.5)% | (1,773) |
| Total Revenue by Product Category | $172,347 | $152,191 | 13.2% | $20,156 |
The increase in revenue for three months ended March 31, 2025 as compared to the same period in 2024 reflects higher sales of single wafer cleaning, Tahoe and semi-critical cleaning equipment, and ECP (front-end and packaging), furnace and other technologies, partly offset by lower Advanced packaging (excluding ECP), services and spares. The increased demand is due in part to a longer term commitment by our mainland China-based customers to increase production capacity to achieve a greater share of the global semiconductor market.
Cost of Revenue and Gross Margin
(in thousands)
| Three Months Ended March 31, 2025 | 2024 | % Change 2025 v 2024 | Absolute Change 2025 v 2024 | |
|---|---|---|---|---|
| Cost of revenue | $89,797 | $73,070 | 22.9% | $16,727 |
| Gross profit | 82,550 | 79,121 | 4.3% | 3,429 |
| Gross margin | 47.9% | 52.0% | (4.1)% | (409)bps |
Cost of revenue and gross profit increased in the three months ended March 31, 2025 as compared to the corresponding period in 2024 due to the increased sales volume, partly offset by a decrease in gross margin. The decrease in gross margin versus the prior-year period was primarily due to revenue mix between product categories, and a higher provision for inventory. Gross margin may vary from period to period, primarily related to the level of utilization and the timing and mix of revenue. We expect gross margin to be between 42.0% and 48.0% for the foreseeable future.
Operating Expenses
(in thousands)
| Three Months Ended March 31, 2025 | 2024 | % Change 2025 v 2024 | Absolute Change 2025 v 2024 | |
|---|---|---|---|---|
| Sales and marketing expense | $16,343 | $14,173 | 15.3% | $2,170 |
| Research and development expense | 27,503 | 23,918 | 15.0% | 3,585 |
| General and administrative expense | 12,927 | 15,798 | (18.2)% | (2,871) |
| Total operating expenses | $56,773 | $53,889 | 5.4% | $2,884 |
Sales and marketing expense increased in the three months ended March 31, 2025 as compared to the corresponding period in 2024, reflecting an increase of $2.6 million due to personnel costs, and a net increase of $0.5 million for commissions, travel & entertainment, outside services and other expenses, offset by a $0.9 million decrease in stock-based compensation.
Sales and marketing expense consists primarily of:
- compensation of personnel associated with pre-sale and after-sale services and support and other sales and marketing activities, including stock-based compensation;
- sales commissions paid to independent sales representatives;
- fees paid to sales consultants;
- cost of trade shows;
- costs of tools built for promotional purposes for potential new customers;
- travel and entertainment; and
- rent and utilities.
We expect that, for the foreseeable future, sales and marketing expenses will increase in dollars, as we incur additional costs associated with growing our customer base in mainland China and regions outside of mainland China.
Research and development expense increased in the three months ended March 31, 2025 as compared to the corresponding period in 2024, reflecting an increase of $3.9 million R&D-related personnel costs, an increase of $1.0 million in costs of components for tools built for product development purposes, and a net increase of $0.4 million in depreciation, outside services and other R&D-related costs, offset by a decrease of $1.7 million in stock-based compensation.
Research and development expense represented 16.0% and 15.7% of our revenue in the three months ended March 31, 2025 and 2024, respectively. Without reduction by grant amounts received from mainland China governmental authorities (see ‘–Mainland China Government Research and Development Funding’’), gross research and development expense totaled $27.8 million, or 16.1% of total revenue, in the three months ended March 31, 2025 as compared to $24.4 million, or 16.0% of revenue, in the corresponding period in 2024.
Research and development expense consists primarily of:
- compensation of personnel associated with our research and development activities, including stock based compensation;
- costs of components and other research and development supplies;
- costs of tools built for product development purposes;
- travel expense associated with the research of technical requirements for product development purposes and testing of concepts under consideration;
- amortization of costs of software used for research and development purposes; and
- rent and utilities.
We expect that, for the foreseeable future, research and development expenses will increase in dollars, as we incur additional costs to expand our product portfolio to address additional production steps and expand our research and development team to new regions.
General and administrative expense decreased in the three months ended March 31, 2025 as compared to the corresponding period in 2024, primarily reflecting a $0.9 million net increase in personnel and professional services costs, offset by a $1.9 million decrease in stock-based compensation, a $1.2 million decrease in allowance for credit losses, and a $0.7 million decrease in other costs related to general and administrative expenses.
General and administrative expense consists primarily of:
- compensation of executive, accounting and finance, human resources, information technology, and other administrative personnel, including stock-based compensation;
- professional fees, including accounting and corporate legal and defense fees;
- other corporate expenses including insurance;
- allowance for credit losses; and
- rent and utilities.
We expect that, for the foreseeable future, general and administrative expenses will increase in dollars, as we incur additional costs associated with growing our business, operating ACM Research, as a public company in the United States and operating ACM Shanghai as a public company in mainland China.
Interest income, net, Other expense, net
(in thousands)
| Three Months Ended March 31, 2025 | 2024 | % Change 2025 v 2024 | Absolute Change 2025 v 2024 | |
|---|---|---|---|---|
| Interest income | $3,339 | $1,774 | 88.2% | $1,565 |
| Interest expense | (1,558) | (783) | 99.0% | (775) |
| Interest income, net | $1,781 | $991 | 79.7% | $790 |
| Other (expense) income, net | $(262) | $3,080 | -108.5% | $(3,342) |
37
Interest income, net consists of interest earned on our cash and cash equivalents, restricted cash accounts, and short-term and long-term time deposits, offset by interest expense incurred from outstanding short-term and long-term borrowings. Interest income (expense), net increased in the three months ended March 31, 2025 as compared to the corresponding period in 2024, as a result of changes in balances of cash, cash equivalents, time deposits, and debt, together with changes in interest rates earned or expensed on the respective balances.
Other income (expense), net primarily reflects (a) loss recognized from the impact of exchange rates on our working-capital which was $(0.6) million for the three months ended March 31, 2025 compared to $1.4 million recognized from the impact of exchange rates on our working capital for the three months ended March 31, 2024, and (b) government subsidies, as described under “—Mainland China Government Research and Development Funding” above, and other factors.
Realized gain and unrealized loss from short-term investment, and income (loss) from equity investments.
(in thousands)
| Three Months Ended March 31, 2025 | 2024 | % Change 2025 v 2024 | Absolute Change 2025 v 2024 | |
|---|---|---|---|---|
| Realized gain from sale of short-term investments | $— | $273 | (100.0)% | $(273) |
| Unrealized loss on short-term investments | (1,082) | (2,595) | (58.3)% | $1,513 |
| Income (loss) from equity method investments | $952 | $(520) | (283.1)% | $1,472 |
We recorded a realized gain from sale of short term investments of nil for the three months ended March 31, 2025 as compared to $0.3 million in the prior-year period due to a sale of short-term investments (note 14).
We recorded an unrealized loss on short term investments of $1.1 million for the three months ended March 31, 2025 as compared to an unrealized loss of $2.6 million for the same period in 2024, based on a change in market value of ACM Shanghai’s short-term investments (note 14).
Income (loss) from equity investments was $1.0 million for the three months ended March 31, 2025 as compared to loss from equity method investments of $0.5 million in the same period in 2024 due to an increase of net income from investments in affiliates (note 13).
Income Tax Expense
The following presents components of income tax expense for the indicated periods:
(in thousands)
| Three Months Ended March 31, 2025 | 2024 | |
|---|---|---|
| Income tax expense | $(2,153) | $(4,369) |
We recognized a tax expense of $2.2 million for the three months ended March 31, 2025 as compared to a tax expense of $4.4 million for the prior year period. The tax expense for the three months ended March 31, 2025 primarily resulted from the tax effect of a decrease in our effective income tax rate applied to a slight increase in operating profit for the period. The decrease in our effective income tax rate for the three months ended March 31, 2025 compared to the same period of the prior year was primarily due to a lower estimated effective tax rate for ACM Shanghai and other factors.
Our effective tax rate differs from statutory rates of 21% for U.S. federal income tax purposes and 25% for mainland China income tax purposes due to the effects of the valuation allowance and certain permanent differences as it pertains to book-tax differences in the treatment of stock-based compensation and non-U.S. research expenses. Our four mainland China subsidiaries, ACM Shanghai, ACM Wuxi, ACM Beijing, and ACM Lingang, are liable for mainland China corporate income taxes at the rates of 15%, 25%, 25%, and 25%, respectively. Pursuant to the Corporate Income Tax Law of mainland China, our mainland China subsidiaries generally would be liable for mainland China corporate income taxes at a rate of 25%. According to Guoshuihan 2009 No. 203, an entity certified as an “advanced and new technology enterprise” is entitled to a preferential income tax rate of 15%. ACM Shanghai was certified as an “advanced and new technology enterprise” in 2012 and again in 2016, 2018, 2021,and 2024 effective until December 31, 2026.
We file income tax returns in the United States and state and foreign jurisdictions. All tax returns will remain open for examination by the federal and state authorities for three and four years, respectively, from the date of utilization of any net operating loss or credits. Certain tax years are subject to foreign income tax examinations by tax authorities until the statute of limitations expire.
Net Income Attributable to Non-Controlling Interests
(in thousands)
| Three Months Ended March 31, 2025 | 2024 | % Change 2025 v 2024 | Absolute Change 2025 v 2024 | |
|---|---|---|---|---|
| Net income attributable to non-controlling interests | $4,633 | $4,659 | (0.6)% | $(26) |
ACM Research owns 81.1% of ACM Shanghai’s (note 1) outstanding shares which is reflected in our condensed consolidated financial statements. We reflect the portion of net income allocable to the minority holders of ACM Shanghai shares as net income attributable to non-controlling interests.
Foreign currency translation adjustment
(in thousands)
| Three Months Ended March 31, 2025 | 2024 | % Change 2025 v 2024 | Absolute Change 2025 v 2024 | |
|---|---|---|---|---|
| Foreign currency translation adjustment | $1,750 | $(6,829) | (125.6)% | $8,579 |
We recorded a gain of foreign currency translation adjustment of $1.8 million for the three months ended March 31, 2025, as compared to a loss of $6.8 million for the same period in 2024, primarily based on the net effect of RMB to dollar exchange rate fluctuations for the period on the converted value of ACM Shanghai’s RMB-denominated balances to U.S. dollar equivalents.
Comprehensive income attributable to non-controlling interests
(in thousands)
| Three Months Ended March 31, 2025 | 2024 | % Change 2025 v 2024 | Absolute Change 2025 v 2024 | |
|---|---|---|---|---|
| Comprehensive income attributable to non-controlling interests | $4,957 | $3,406 | 45.5% | $1,551 |
Comprehensive income attributable to non-controlling interests for the three months ended March 31, 2025 increased by $1.6 million as compared to the same period in 2024, reflecting a change in net income attributable to the non-controlling interests for the period together with the impact of foreign exchange rate fluctuations on the cumulative balance.
Liquidity and Capital Resources
During the first three months of 2025, we funded our technology development and operations principally through our beginning global cash balances, including the cash balances at ACM Shanghai, borrowings by ACM Shanghai from local financial institutions, our loan from China CITIC Bank, and cash flow from operations.
Cash and cash equivalents, restricted cash, short-term time deposits and long-term time deposits were $498.4 million at March 31, 2025, compared to $441.9 million at December 31, 2024. The $56.5 million increase was primarily driven by $67.2 million net cash provided by financing activities, $5.3 million of cash provided by operations, and a $0.9 million increase from the effect of exchange rate on cash, cash equivalents, restricted cash and non-cash items, offset by a $17.1 million of net cash used in investing activities, excluding the change in net cash related to time deposits.
(In thousands)
| Cash and cash equivalents, restricted cash, and time deposits: | March 31, 2025 | December 31, 2024 |
|---|---|---|
| Cash and cash equivalents and restricted cash | $467,826 | $411,310 |
| Short-term time deposits | 17,202 | 17,277 |
| Long-term time deposits | 13,393 | 13,275 |
| Total | $498,421 | $441,862 |
Our future working capital needs beyond the next twelve months will depend on many factors, including the rate of our business and revenue growth, the payment schedules of our customers, the timing and magnitude of our capital expenditures, and the timing of investment in our research and development as well as sales and marketing. We believe our existing cash and cash equivalents and short-term and long-term time deposits, our cash flow from operating activities, and bank borrowings by us and ACM Shanghai will be sufficient to meet our anticipated cash needs within our longer term planning horizon.
ACM Shanghai has historically participated in certain mainland China government-sponsored grant and subsidy programs, as described under “—Mainland China Government Research and Development Funding” and “—Contractual Obligations” and we expect that ACM Shanghai will continue to take advantage of these programs when they are available and fit with our business strategy. ACM Shanghai generally applies for these grants and subsidies through the applicable mainland China government agency’s defined processes. Periodically, the public relations department researches the availability of these grants and subsidies through mainland China government agencies with whom ACM Shanghai files business surveys and taxes. Management of ACM Shanghai then assesses which grants and subsidies for which ACM Shanghai may be eligible and submits the relevant application. The decision to award the grant to ACM Shanghai is made by the relevant mainland China government agencies based on suitability and the merits of the application. Neither ACM Research, nor ACM Shanghai or any of our other subsidiaries, has any direct relationship with any mainland China government agency, and our anticipated cash needs for the next twelve months neither anticipate, nor require, receipt of any mainland China government grants or subsidies.
To the extent our cash and cash equivalents, cash flow from operating activities and short-term bank borrowings are insufficient to fund our future activities in accordance with our strategic plan, we may determine to raise additional funds through public or private debt or equity financings or additional bank credit arrangements. We also may need to raise additional funds in the event we determine in the future to effect one or more acquisitions of businesses, technologies and products. If additional funding is necessary or desirable, we may not be able to obtain bank credit arrangements or to obtain an equity or debt financing on terms acceptable to us or at all.
Restrictions under mainland China laws and regulations as well as restrictions under ACM Shanghai’s bank loan agreements, may significantly restrict ACM Shanghai’s ability to transfer a portion of ACM Shanghai’s net assets to ACM Research, other subsidiaries of ACM Research and to holders of ACM Research Class A common stock. See “Item 1A. Risk Factors – Regulatory Risks – Mainland China's currency exchange control and government restrictions on investment repatriation may impact our ability to transfer funds outside of mainland China, which could materially and adversely affect our ability to grow, make investments or acquisitions that could benefit our business, otherwise fund and conduct our business, or pay dividends on our common stock” in our Annual Report.
For the three months ended March 31, 2025 and 2024, with the exception of sales and services-related transfer-pricing payments in the ordinary course of business, no transfers or distributions have been made between ACM Research, and its subsidiaries, including ACM Shanghai, or to holders of ACM Research Class A common stock.
Our cash and cash equivalents at March 31, 2025 were held for working capital purposes and other potential investments. ACM Shanghai, our only direct mainland China subsidiary, is, however, subject to mainland China restrictions on distributions to equity holders. The use of proceeds raised by the STAR Market IPO, without further approvals, are limited to specific usage. Our accounts receivable balance fluctuates from period to period, which affects our cash flow from operating activities. Fluctuations vary depending on cash collections, client mix, and the timing of shipment and acceptance of our tools.
ACM Research has never declared or paid cash dividends on our capital stock. ACM Research intends to retain all available funds and any future earnings to support the operation of and to finance the growth and development of our business and do not anticipate paying any cash dividends in the foreseeable future.
Cash Flow Provided by Operating Activities. Net cash provided by operating activities of $4.9 million during the three months ended March 31, 2025 consisted of:
(In thousands)
| Three Months Ended March 31, 2025 | 2024 | |
|---|---|---|
| Net Income | $25,013 | $22,092 |
| Non-cash operating lease cost | 1,086 | 973 |
| Provision for inventory | 4,523 | 1,025 |
| (Reversal) provision for credit losses | (9) | 1,171 |
| Depreciation and amortization | 3,017 | 2,518 |
| Realized gain on short-term investment | — | (273) |
| Income (loss) from equity method investments | (952) | 520 |
| Unrealized loss on short-term investments | 1,082 | 2,595 |
| Deferred income taxes | (1,661) | (1,129) |
| Stock-based compensation | 9,817 | 14,569 |
| Net changes in operating assets and liabilities | (37,673) | (53,710) |
| Others | 1,039 | — |
| Net cash flow provided by (used in) operating activities | 5,282 | (9,649) |
41
Significant net changes in operating asset and liability accounts primarily include the following:
- uses of cash: a $23.4 million net decrease in accounts payable, a $15.1 million increase in inventories, net (note 5), a $6.6 million decrease in income taxes payable, a $3.1 million increase in prepaid expenses and other current assets, and a $2.8 million decrease in customer advances.
- sources of cash: a $7.1 million decrease in other receivables, a $2.4 million increase in other payables and accrued expenses, and a $2.2 million increase in deferred revenue.
Cash Flow Used in Investing Activities. Net cash used in investing activities, excluding the change in net cash related to time deposits, for the three months ended March 31, 2025 was ($17.1 million), primarily consisting of ($17.1 million) for purchase of property, plant and equipment, and intangible assets.
Cash Flow Provided by Financing Activities. Net cash provided by financing activities for the three months ended March 31, 2025 was $67.2 million, primarily consisting of $52.2 million in net proceeds from long-term borrowing (note 11), and $22.7 million proceeds from exercise of stock options, partly offset by ($7.9 million) net in next repayments of short-term borrowings.
We and ACM Shanghai, together with the subsidiaries of ACM Shanghai, have short-term and long-term borrowings with the following banks:
(in thousands)
| Lender | Agreement Date | Maturity Date | Annual Interest Rate | Maximum Borrowing Amount(1) | Amount Outstanding at March 31, 2025 |
|---|---|---|---|---|---|
| China CITIC Bank (2) | July 2023 | Repayable by installments and the last installments repayable in December 2025 | 3.45% | RMB200,000 | RMB100,201 |
| $27,860 | $13,958 | ||||
| China CITIC Bank (2) | January 2025 | Repayable by installments and the last installments repayable in January 2028 | 3.60% | RMB200,000 | RMB199,598 |
| $27,860 | $27,804 | ||||
| China Everbright Bank | December 2024 | September 2027 | 2.60% | RMB600,000 | RMB399,297 |
| $83,580 | $55,622 | ||||
| China Merchants Bank | August 2024 | August 2025 | 2.28%~2.6% | RMB200,000 | RMB139,089 |
| $27,860 | $19,375 | ||||
| Bank of China | September 2024 | September 2025 | 2.50%-2.75% | RMB400,000 | RMB243,174 |
| $55,720 | $33,874 | ||||
| Shanghai Pudong Development Bank | December 2024 | September 2025 | 2.60% | RMB300,000 | NIL |
| $41,790 | $— | ||||
| Industrial and Commercial Bank of China | November 2024 | November 2027 | 2.35% | RMB300,000 | RMB150,098 |
42
| $41,790 | $20,909 | ||||
| China Merchants Bank | August 2024 | August 2034 | 2.95% | RMB1,000,000 | RMB21,525 |
| $139,300 | $2,998 | ||||
| Bank of China | November 2024 | November 2035 | 2.70% | RMB1,000,000 | RMB6,825 |
| $139,300 | $951 | ||||
| China Merchants Bank | November 2020 | Repayable by installments and the last installments repayable in November 2030 | 3.65% | RMB128,500 | RMB79,353 |
| $17,900 | $11,054 | ||||
| Agricultural Bank of China | April 2024 | Repayable by installments and the last installments repayable in April 2034 | 2.53%-2.78% | RMB300,000 | RMB93,604 |
| $41,790 | $13,040 | ||||
| Bank of Shanghai | December 2022 | April 2025 | 2.85% | RMB100,000 | RMB100,079 |
| $13,930 | $13,941 | ||||
| China CITIC Bank | August 2023 | Repayable by installments and the last installments repayable in August 2025 | 3.10% | RMB100,000 | RMB99,786 |
| $13,930 | $13,900 | ||||
| Total | $672,610 | $227,426 |
(1) Converted from RMB to dollars as of March 31, 2025. The loan from China Merchants Bank is secured by a pledge of the property of ACM Lingang and guaranteed by ACM Shanghai, as described above under “—Contractual Obligations.”
(2) This China CITIC bank facility agreement is with ACM Research, Inc.
Loan Covenants
In January 2025, ACM Shanghai secured a long-term loan facility with China Merchants Bank (note 11) for ACM Shanghai’s project expenditures. The facility contains certain covenants, which requires ACM Shanghai to either repay 50% of the outstanding principal within two months, or repay the loan in accordance with an accelerated payment schedule, if ACM Shanghai does not complete, within three years after then initial drawdown, or before January 2028, a Private Offering with more than RMB900 million of proceeds.
In February 2025, ACM Shanghai secured a long-term loan facility with the Bank of China (note 11) for ACM Shanghai’s project expenditures. The facility requires ACM Shanghai’s year-end outstanding interest-bearing debt not to exceed five times of its annual EBITDA, and to comply with other non-financial covenants, or Bank of China has the right to suspend the facility, or request ACM Shanghai to accelerate repayment or provide credit enhancement.
Effect of exchange rate changes on cash, cash equivalents and restricted cash. The effect of exchange rate cash, and cash equivalents was $0.9 million during the first three months ended March 31, 2025. The impact of fluctuations of the RMB to U.S. dollar currency exchange rate on a significant balance of these items held in RMB-denominated accounts (note 2) contributed to the change.
Contractual Obligations
Grant Contract for State-owned Construction Land Use Right in Shanghai City
In 2020 ACM Shanghai, through its wholly-owned subsidiary ACM Lingang, entered into a Grant Contract for State-owned Construction Land Use Right in Shanghai City (Category of R&D Headquarters and Industrial Projects), or the Grant Agreement, with the China (Shanghai) Pilot Free Trade Zone Lin-gang Special Area Administration, or the Grantor. ACM Lingang obtained rights to use approximately 43,000 square meters (10.6 acres) of land in the East China Silicon Hub of Lin-gang Special Area of China (Shanghai) Pilot Free Trade Zone, or the Land Use Right, for a period of fifty years, commencing on the date of delivery of the land in July 2020, which we refer to as the Delivery Date.
In exchange for its land use rights, ACM Lingang paid aggregate grant fees of RMB 61.7 million ($9.5 million), or the Grant Fees, and a performance deposit of RMB 12.3 million ($1.9 million), which is equal to 20% of the aggregate grant fees, to secure its achievement of the certain performance milestones. As of March 31, 2025, ACM Lingang had not yet officially achieved the Construction Completion Milestone and the Production Start Milestones, however the performance deposit has been refunded in full (note 7). ACM Lingang has been notified that the Lin-gang Special Area Administration plans to enter into supplementary land grant agreements to adjust the performance terms, including the extension of Construction Completion and Production Start Milestones. Based on current expectations, ACM Lingang believes it will meet the updated requirements and no penalties will be incurred. We cannot guarantee that ACM Lingang will achieve the missed milestones in 2025, or even if it does achieve the milestones in 2025, that it will not face penalties related to the original or updated agreements.
In addition to the milestones, covenants in the Grant Agreement require that, among other things, ACM Lingang will be required to pay liquidated damages in the event that within seven years after the Delivery Date, or prior to July 9, 2027, it does not (i) generate a minimum specified amount of annual sales of products manufactured on the granted land or (ii) pay at least RMB 157.6 million ($22.2 million) in annual total taxes (including value-added taxes, corporate income tax, personal income taxes, urban maintenance and construction taxes, education surcharges, stamp taxes, and vehicle and shipping taxes) as a result of operations in connection with the granted land.
If the total tax revenue of the project fails to reach but is no less than 80% of the standard agreed under the Grant Agreement, ACM Lingang shall pay 20% of the actual shortfall amount of the tax revenue as liquidated damages. If the total tax revenue of the project fails to reach 80% of the standard agreed under the Grant Agreement within 1 month after the agreed date of reaching target production, the Grantor is entitled to terminate the Grant Agreement, take back the Land Use Right, and shall refund the Grant Fees for the remaining land use term to ACM Lingang.
If the Grant Agreement is terminated because of breach of any terms above, the Grantor shall take back the buildings, fixtures and auxiliary facilities on the land area and provide ACM Lingang with corresponding compensation according to the residual value of the buildings, fixtures and auxiliary facilities when they are taken back.
How We Evaluate Our Operations
We present information below with respect to four measures of financial performance:
- We define shipments of tools to include (a) a repeat shipment to a customer of a type of tool that the customer has previously accepted, for which we recognize revenue upon shipment or delivery, and (b) a first-time shipment of a first tool to a customer on an approval basis, for which we may recognize revenue in the future if contractual conditions are met, or if a purchase order is received.
- We define “adjusted EBITDA” as net income excluding interest expense (net), income tax benefit (expense), depreciation and amortization, unrealized (gain) loss on short-term investments, and stock-based compensation. We define adjusted EBITDA to also exclude restructuring costs, although we have not incurred any such costs to date.
- We define “free cash flow” as net cash provided by operating activities less purchases of property and equipment (net of proceeds from disposals) and purchase of short-term and long-term investments.
- We define “adjusted operating income (loss)” as our income (loss) from operations excluding stock-based compensation.
These financial measures are not based on any standardized methodologies prescribed by accounting principles generally accepted in the United States, or GAAP, and are not necessarily comparable to similarly titled measures presented by other companies.
We have presented shipments, adjusted EBITDA, free cash flow and adjusted operating income (loss) because they are key measures used by our management and board of directors to understand and evaluate our operating performance, to establish budgets and to develop operational goals for managing our business. We believe that these financial measures help identify underlying trends in our business that could otherwise be masked by the effect of the expenses that we exclude. In particular, we believe that the exclusion of the expenses eliminated in calculating adjusted EBITDA and adjusted operating income (loss) can provide useful measures for period-to-period comparisons of our core operating performance and that the exclusion of property and equipment purchases from operating cash flow can provide a usual means to gauge our capability to generate cash. Accordingly, we believe that these financial measures provide useful information to investors and others in understanding and evaluating our operating results, enhancing the overall understanding of our past performance and future prospects, and allowing for greater transparency with respect to key financial metrics used by our management in its financial and operational decision-making.
Shipments, adjusted EBITDA, free cash flow and adjusted operating income (loss) are not prepared in accordance with GAAP, and should not be considered in isolation of, or as an alternative to, measures prepared in accordance with GAAP.
Shipments
We consider shipments a key operating metric as it reflects the total value of products delivered to customers and prospective customers by our productive assets.
Shipments consist of two components:
- a shipment to a customer of a type of tool that the customer has previously accepted, for which we recognize revenue when the tool is delivered; and
- a shipment to a customer of a type of tool that the customer is receiving and evaluating for the first time, in each case a first tool, for which we may recognize revenue at a later date, subject to the customer’s acceptance of the tool upon the tool’s satisfaction of applicable contractual requirements or subject to the customer’s subsequent discretionary commitment to purchase the tool.
First tool shipments can be made to either an existing customer that has not previously accepted that specific type of tool in the past ─ for example, a delivery of a SAPS V tool to a customer that previously had received only SAPS II tools ─ or to a new customer that has never purchased any tool from us.
Shipments in the three months ended March 31, 2025 totaled $156.7 million, as compared to $245.6 million for the same periods in 2024. Repeat tool shipments in the three months ended March 31, 2025 totaled $60.8 million, as compared to $118.6 million for same periods in 2024. First tool shipments in the three months ended March 31, 2025 totaled $95.9 million, as compared to $127.0 million for the same periods in 2024.
The dollar amount attributed to a first tool shipment is equal to the consideration we expect to receive if any and all contractual requirements are satisfied and the customer accepts the tool, or if the customer subsequently determines in its discretion to purchase the tool. There are a number of limitations related to the use of shipments in evaluating our business, including that customers have significant, or in some cases total, discretion in determining whether to accept or purchase our tools after evaluation and their decision not to accept or purchase delivered tools is likely to result in our inability to recognize revenue from the delivered tools. “First tool” shipments reflect the value of incremental new products under evaluation delivered to our customers or prospective customers for a given period and is used as an internal key metric to reflect future potential revenue opportunity. The cumulative cost of “first tool” shipments under evaluation at customers which have not been accepted by the customer is carried at cost and reflected in finished goods inventory (see Note 5 to the condensed consolidated financial statements included in this report). “First tool” shipments exclude deliveries to customers for which ACM Research does not have a basis to expect future revenue.
Adjusted EBITDA
There are a number of limitations related to the use of adjusted EBITDA rather than net income (loss), which is the nearest GAAP equivalent. Some of these limitations are:
- adjusted EBITDA excludes depreciation and amortization and, although these are non-cash expenses, the assets being depreciated or amortized may have to be replaced in the future;
- we exclude stock-based compensation expense from adjusted EBITDA and adjusted operating income (loss), although (a) it has been, and will continue to be for the foreseeable future, a significant recurring expense for our business and an important part of our compensation strategy and (b) if we did not pay out a portion of our compensation in the form of stock-based compensation, the cash salary expense included in operating expenses would be higher, which would affect our cash position;
- the expenses and other items that we exclude in our calculation of adjusted EBITDA may differ from the expenses and other items, if any, that other companies may exclude from adjusted EBITDA when they report their operating results;
- adjusted EBITDA does not reflect changes in, or cash requirements for, working capital needs;
- adjusted EBITDA does not reflect interest expense, or the requirements necessary to service interest or principal payments on debt;
- adjusted EBITDA does not reflect income tax expense (benefit) or the cash requirements to pay taxes;
- adjusted EBITDA does not reflect historical cash expenditures or future requirements for capital expenditures or contractual commitments; and
- adjusted EBITDA includes expense reductions and non-operating other income attributable to mainland China governmental grants, which may mask the effect of underlying developments in net income, including trends in current expenses and interest expense, and free cash flow includes mainland China governmental grants, the amount and timing of which can be difficult to predict and are outside our control.
The following table reconciles net income, the most directly comparable GAAP financial measure, to adjusted EBITDA:
(in thousands)
| Adjusted EBITDA Data: | Three Months Ended March 31, 2025 | 2024 | % Change 2025 v 2024 | Absolute Change 2025 v 2024 |
|---|---|---|---|---|
| Net Income | $25,013 | $22,092 | 13.2% | $2,921 |
| Interest income, net | (1,781) | (991) | 79.7% | (790) |
| Income tax expense | 2,153 | 4,369 | -50.7% | (2,216) |
| Depreciation and amortization | 3,017 | 2,518 | 19.8% | 499 |
| Stock based compensation | 9,817 | 14,569 | -32.6% | (4,752) |
| Unrealized loss on short-term investments | 1,082 | 2,595 | -58.3% | (1,513) |
| Adjusted EBITDA | $39,301 | $45,152 | (13.0%) | $(5,851) |
We do not exclude from adjusted EBITDA expense reductions and non-operating other income attributable to mainland China governmental grants because we consider and incorporate the expected amounts and timing of those grants in incurring expenses and capital expenditures. If we did not receive the grants, our cash expenses therefore would be lower, and our cash position would not be affected, to the extent we have accurately anticipated the amounts of the grants. For additional information regarding our mainland China grants, please see “—Mainland China Government Research and Development Funding.”
Free Cash Flow
The following table reconciles net cash provided by (used in) operating activities, the most directly comparable GAAP financial measure, to free cash flow:
(in thousands)
| Free Cash Flow Data: | Three Months Ended March 31, 2025 | 2024 | % Change 2025 v 2024 | Absolute Change 2025 v 2024 |
|---|---|---|---|---|
| Net cash provided by (used in) operating activities | $5,282 | $(9,649) | (154.7%) | $14,931 |
| Purchase of property and equipment | (16,726) | (25,419) | (34.2%) | 8,693 |
| Purchase of short-term and long-term investments | — | (7,397) | (100.0%) | 7,397 |
| Free cash flow | $(11,444) | $(42,465) | (73.0%) | $31,021 |
The improvement in free cash flow for the three months ended March 31, 2025 as compared to the same period in 2024 reflected the factors driving net cash used in operating activities, an increase of purchases of property and equipment, and long-term investment. Consistent with our methodology for calculating adjusted EBITDA, we do not adjust free cash flow for the effects of mainland China government subsidies, because we take those subsidies into account in incurring expenses and capital expenditures. We do not adjust free cash flow for the effects of time-deposits, which for our internal purposes are considered as largely similar to cash.
Adjusted Operating Income
Adjusted operating income excludes stock-based compensation from income from operations. Although stock-based compensation is an important aspect of the compensation of our employees and executives, determining the fair value of certain of the stock-based instruments we utilize involves judgment and estimation and the expense recorded may bear little resemblance to the actual value realized upon the vesting or future exercise of the related stock-based awards. Furthermore, unlike cash compensation, the value of stock options, which is an element of our ongoing stock-based compensation expense, is determined using a complex formula that incorporates factors. Management believes it is useful to exclude stock-based compensation in order to better understand the long-term performance of our core business and to facilitate comparison of our results to those of peer companies. The use of non-GAAP financial measures excluding stock-based compensation has limitations, however. If we did not pay out a portion of our compensation in the form of stock-based compensation, the cash salary expense included in operating expenses would be higher and our cash holdings would be less. The following tables reflect the exclusion of stock-based compensation, or SBC, from line items comprising income from operations:
(in thousands)
| Three Months Ended March 31, 2025 Actual (GAAP) | SBC | Adjusted (Non- GAAP) | 2024 Actual (GAAP) | SBC | Adjusted (Non-GAAP) | |
|---|---|---|---|---|---|---|
| Revenue | $172,347 | $- | $172,347 | $152,191 | $- | $152,191 |
| Cost of revenue | (89,797) | (529) | (89,268) | (73,070) | (781) | (72,289) |
| Gross profit | 82,550 | (529) | 83,079 | 79,121 | (781) | 79,902 |
| Operating expenses: | ||||||
| Sales and marketing | (16,343) | (2,157) | (14,186) | (14,173) | (3,027) | (11,146) |
| Research and development | (27,503) | (2,775) | (24,728) | (23,918) | (4,503) | (19,415) |
| General and administrative | (12,927) | (4,356) | (8,571) | (15,798) | (6,258) | (9,540) |
| Income (loss) from operations | $25,777 | $(9,817) | $35,594 | $25,232 | $(14,569) | $39,801 |
Market risk
As filed, 311 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
Our market risks and the ways we manage them are summarized in the section captioned “Part II, Item 7A. Quantitative and Qualitative Disclosures About Market Risk” in our Annual Report. There have been no material changes in the first three months of 2024 to our market risks or to our management of such risks.
Controls and procedures
As filed, 1,824 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
Evaluation of Disclosure Controls and Procedures
Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures pursuant to Rule 13a-15 under the Securities Exchange Act of 1934, or the Exchange Act, as of March 31, 2025. In designing and evaluating the disclosure controls and procedures, our management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives. In addition, the design of disclosure controls and procedures must reflect the fact that there are resource constraints and that our management is required to apply its judgment in evaluating the benefits of possible controls and procedures relative to their costs.
Based on such evaluation, our Chief Executive Officer and Chief Financial Officer concluded that, as of March 31, 2025, our disclosure controls and procedures were effective to provide reasonable assurance that information we are required to disclose in reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission rules and forms, and that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure.
Changes in Internal Control Over Financial Reporting
There were no changes in our internal control over financial reporting that occurred during the quarter ended March 31, 2025, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
Risk factors
As filed, 3,689 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
Except as set forth below, there were no material changes to the risk factors discussed in Item 1A. “Risk Factors” of Part I in our Annual Report. In addition to the other information set forth in this report, you should carefully consider those risk factors, which could materially affect our business, financial condition and future operating results. Those risk factors are not the only risks facing our company. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial also may have a material adverse effect on our business, financial condition and operating results.
We may be subject to risks related to recent U.S. tariffs on the semiconductor industry
On April 5, 2025, the Trump administration imposed sweeping new “reciprocal” tariffs on most imported items, including a “baseline” rate of 10% on most countries. This baseline 10% rate was scheduled to increase on various countries on April 9, 2025, but was subject to a 90-day “pause” for the administration to negotiate agreements with affected countries. However, full reciprocal tariffs did go into effect on China, which currently stand at 125%. Earlier 20% tariffs against China imposed under an executive order targeting the fentanyl import trade “stack” on top of the reciprocal tariffs, such that China is subject to 145% tariffs. Additional 25% tariffs may also apply to goods from China that are subject to earlier duties imposed by the first Trump Administration under Section 301 of the Trade Act of 1974.
Semiconductors are currently exempted from coverage of the reciprocal tariffs (including the 125% reciprocal tariffs on China). This exemption was later clarified to include certain electronic items incorporating semiconductors. However, this exemption may be temporary as the U.S. Department of Commerce on April 1, 2025, initiated an investigation under Section 232 of the Trade Expansion Act of 1962 to assess the national security implication of imports of semiconductors, semiconductor manufacturing equipment, and derivative products. Under Section 232, the Department of Commerce has 270 days (by December 27, 2025) to complete its investigation, although the Trump administration has indicated a desire to finish on a timeline of a few months. After that, the administration may take measures to address national security concerns, such as imposing specific tariffs on semiconductors or taking other actions to curtail imports.
As a company that designs and manufactures equipment and products used in the semiconductor industry, we are exposed to risks arising from these proposed tariffs due to our reliance on global supply chains. Tariffs may also disrupt the global electronics supply chain, as semiconductors are critical components in products such as servers, smartphones, and automotive systems. Increased costs for our customers could lead to reduced demand for our products, particularly in price-sensitive markets, which may adversely affect our revenue and market share. Furthermore, the Section 232 national security investigation into semiconductors (as well as the overall tariff regime) introduces additional uncertainty, as it could result in broader trade restrictions or changes to import policies that further impact our ability to source raw materials and sell our products efficiently.
The uncertainty surrounding the current semiconductor Section 232 investigation, its implementation timeline, and other issues, combined with the potential for retaliatory trade actions from key markets like China, poses a significant risk to our financial condition, results of operations, and competitive position in the global market.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2025-03-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2025-01-01 to 2025-03-31 | $172.3m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Cost of revenue | 3 months2025-01-01 to 2025-03-31 | $89.8m | us-gaap:CostOfRevenue |
| Gross profit | 3 months2025-01-01 to 2025-03-31 | $82.5m | us-gaap:GrossProfit |
| Research and development | 3 months2025-01-01 to 2025-03-31 | $27.5m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months2025-01-01 to 2025-03-31 | $25.8m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2025-01-01 to 2025-03-31 | $1.6m | us-gaap:InterestExpenseNonoperating |
| Income tax | 3 months2025-01-01 to 2025-03-31 | $2.2m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2025-01-01 to 2025-03-31 | $20.4m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2025-01-01 to 2025-03-31 | $0.30 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2025-01-01 to 2025-03-31 | $0.32 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2025-01-01 to 2025-03-31 | 66,952,774 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 3 months2025-01-01 to 2025-03-31 | $5.3m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 3 months2025-01-01 to 2025-03-31 | $16.7m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2025-03-31 | $457.2m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2025-03-31 | $1.55bn | us-gaap:AssetsCurrent |
| Total assets | At period end2025-03-31 | $1.93bn | us-gaap:Assets |
| Current liabilities | At period end2025-03-31 | $628.9m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2025-03-31 | $778.4m | us-gaap:Liabilities |
| Long-term debt | At period end2025-03-31 | $134.5m | us-gaap:LongTermDebtNoncurrent |
| Current portion of debt | At period end2025-03-31 | $67.9m | us-gaap:LongTermDebtCurrent |
| Short-term borrowings | At period end2025-03-31 | $25.0m | us-gaap:ShortTermBorrowings |
| Shareholders' equity | At period end2025-03-31 | $949.1m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001680062-25-000010. Last ingested by Listed: Nov 6, 2026, 21:36 ET. Listed shows no prices and gives no investment advice.